EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access

Comparison of SB17 and reference ustekinumab in healthy adults: A randomized, double-blind, single-dose, phase I study

Hansol Jeong, Taeseung Kang, Jiyoon Lee, Seongsik Im

Int. Journal of Clinical Pharmacology and Therapeutics · 2024

DOI: 10.5414/cp204492 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2024. Verfasst von Hansol Jeong und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Ustekinumab, Biosimilar Pharmaceuticals. Die Arbeit wurde bisher 10-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabBiosimilar PharmaceuticalsAdultHumansUnited StatesArea Under CurveHealthy VolunteersSingle-Blind MethodTherapeutic EquivalencyDouble-Blind Method

Substanzen

UstekinumabBiosimilar Pharmaceuticals

Zitieren

APA

Jeong, H., Kang, T., Lee, J., & Im, S. (2024). Comparison of SB17 and reference ustekinumab in healthy adults: A randomized, double-blind, single-dose, phase I study. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204492

Vancouver

Jeong H, Kang T, Lee J, Im S. Comparison of SB17 and reference ustekinumab in healthy adults: A randomized, double-blind, single-dose, phase I study. Int. Journal of Clinical Pharmacology and Therapeutics. 2024. doi:10.5414/cp204492

BibTeX
@article{Jeong2024,
  author = {Jeong, Hansol and Kang, Taeseung and Lee, Jiyoon and Im, Seongsik},
  title = {Comparison of SB17 and reference ustekinumab in healthy adults: A randomized, double-blind, single-dose, phase I study},
  journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
  year = {2024},
  doi = {10.5414/cp204492}
}
Kostenlos starten →